Clearpoint Neuro Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.21
- Today's High:
- $5.39
- Open Price:
- $5.32
- 52W Low:
- $6.55
- 52W High:
- $16.96
- Prev. Close:
- $5.36
- Volume:
- 57052
Company Statistics
- Market Cap.:
- $168.14 million
- Book Value:
- 1.325
- Revenue TTM:
- $20.95 million
- Operating Margin TTM:
- -86.77%
- Gross Profit TTM:
- $13.53 million
- Profit Margin:
- -86.31%
- Return on Assets TTM:
- -20.29%
- Return on Equity TTM:
- -46.19%
Company Profile
Clearpoint Neuro Inc had its IPO on 2020-02-12 under the ticker symbol CLPT.
The company operates in the Healthcare sector and Medical Devices industry. Clearpoint Neuro Inc has a staff strength of 108 employees.
Stock update
Shares of Clearpoint Neuro Inc opened at $5.32 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.21 - $5.39, and closed at $5.26.
This is a -1.87% slip from the previous day's closing price.
A total volume of 57,052 shares were traded at the close of the day’s session.
In the last one week, shares of Clearpoint Neuro Inc have slipped by -8.36%.
Clearpoint Neuro Inc's Key Ratios
Clearpoint Neuro Inc has a market cap of $168.14 million, indicating a price to book ratio of 5.5232 and a price to sales ratio of 10.2795.
In the last 12-months Clearpoint Neuro Inc’s revenue was $20.95 million with a gross profit of $13.53 million and an EBITDA of $-17893000. The EBITDA ratio measures Clearpoint Neuro Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Clearpoint Neuro Inc’s operating margin was -86.77% while its return on assets stood at -20.29% with a return of equity of -46.19%.
In Q1, Clearpoint Neuro Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 8%.
Clearpoint Neuro Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clearpoint Neuro Inc’s profitability.
Clearpoint Neuro Inc stock is trading at a EV to sales ratio of 9.7535 and a EV to EBITDA ratio of -12.7261. Its price to sales ratio in the trailing 12-months stood at 10.2795.
Clearpoint Neuro Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $50.25 million
- Total Liabilities
- $6.05 million
- Operating Cash Flow
- $-138000.00
- Capital Expenditure
- $138000
- Dividend Payout Ratio
- 0%
Clearpoint Neuro Inc ended 2024 with $50.25 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.25 million while shareholder equity stood at $32.58 million.
Clearpoint Neuro Inc ended 2024 with $320000.00 in deferred long-term liabilities, $6.05 million in other current liabilities, 246000.00 in common stock, $-155976000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $21.79 million and cash and short-term investments were $31.74 million. The company’s total short-term debt was $571,000 while long-term debt stood at $9.91 million.
Clearpoint Neuro Inc’s total current assets stands at $45.99 million while long-term investments were $0 and short-term investments were $9.94 million. Its net receivables were $2.68 million compared to accounts payable of $1.35 million and inventory worth $9.81 million.
In 2024, Clearpoint Neuro Inc's operating cash flow was $-138000.00 while its capital expenditure stood at $138000.
Comparatively, Clearpoint Neuro Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.26
- 52-Week High
- $16.96
- 52-Week Low
- $6.55
- Analyst Target Price
- $18
Clearpoint Neuro Inc stock is currently trading at $5.26 per share. It touched a 52-week high of $16.96 and a 52-week low of $16.96. Analysts tracking the stock have a 12-month average target price of $18.
Its 50-day moving average was $6.16 and 200-day moving average was $8.03 The short ratio stood at 12.46 indicating a short percent outstanding of 0%.
Around 959.8% of the company’s stock are held by insiders while 2065.8% are held by institutions.
Frequently Asked Questions About Clearpoint Neuro Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain. It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.